Trailing-twelve-month (TTM) revenue is $6.44 Billion with a year-over-year growth of +21.49%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $1,488,996,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-30 |
| Q4 FY2025Period ended 2025-12-31 | $1,566,017,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-06 |
| Q1 FY2026Period ended 2026-03-31 | $1,656,944,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-28 |
| Q2 FY2026Period ended 2026-06-30 | $1,729,614,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-30 |
| TTM revenue | $6,441,571,000 |
Current P/S: $43,964,353,100 market capitalization ÷ $6,441,571,000 TTM revenue = 6.83x.
Market capitalization source: FMP quote. Quote observed 2026-09-10T20:00:00.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $1.73B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-11T12:16:39.607Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Medical Office Building Operations | $808M | $803M | $804M | $870M | $878M | N/A |
| Outpatient Medical And Research Portfolio | N/A | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| CANADA | $389M | $435M | $449M | $465M | $527M | $553M |
| UNITED KINGDOM | $25M | $30M | $28M | $29M |
$6.44B
$6.44 Billion
+21.49%
vs. $5.30B a year ago (TTM)
+11.91%
5 Year compound annual growth rate
1 Year
+21.49%
3 Year
+14.66%
5 Year
+11.91%
10 Year
+6.70%
15 Year
+13.76%
20 Year
+15.15%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $5.83B | +$909.71M | +18.47% |
| 2024 | $4.92B | +$426.44M | +9.48% |
| 2023 | $4.50B | +$368.63M | +8.93% |
| 2022 | $4.13B | +$301.19M | +7.87% |
| 2021 | $3.83B | +$32.65M | +0.86% |
| 2020 |
TTM Growth
+21.49%
3-Year CAGR
+14.66%
5-Year CAGR
+11.91%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-11T12:16:39.607Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| N/A |
| N/A |
| N/A |
| $898M |
| Senior Living Operations | $2.2B | $2.3B | $2.7B | $3.0B | $3.4B | $4.3B |
|---|
| Triple Net Leased Properties | $695M | $654M | $598M | $619M | $622M | $602M |
|---|
| $71M |
| UNITED STATES | $3.4B | $3.4B | $3.7B | $4.0B | $4.4B | $5.2B |
|---|
| $3.80B |
| ($77.39M) |
| (2.00%) |
| 2019 | $3.87B | +$126.94M | +3.39% |
| 2018 | $3.75B | +$171.66M | +4.80% |
| 2017 | $3.57B | +$130.63M | +3.79% |
| 2016 | $3.44B | +$157.12M | +4.78% |
